EGFR and lung adenocarcinoma: The reason is that currently FDA-approved targeted drug therapies, such as epidermal growth factor receptor (EGFR) mutation or EML4-ALK fusion-based targeted therapies, are mainly suitable for lung adenocarcinoma (LUAD) but not for LSCC patients.